Syros Pharmaceuticals (NASDAQ:SYRS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research note released on Sunday morning. The brokerage issued a sell rating on the stock.

Syros Pharmaceuticals Price Performance

NASDAQ:SYRS opened at $0.02 on Friday. Syros Pharmaceuticals has a 1-year low of $0.02 and a 1-year high of $6.93. The company has a 50-day moving average of $0.11 and a 200 day moving average of $0.69. The firm has a market cap of $649,334.40, a PE ratio of -0.01 and a beta of 1.31.

Hedge Funds Weigh In On Syros Pharmaceuticals

A hedge fund recently bought a new stake in Syros Pharmaceuticals stock. Two Sigma Securities LLC bought a new position in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 107,742 shares of the company’s stock, valued at approximately $25,000. Two Sigma Securities LLC owned 0.40% of Syros Pharmaceuticals as of its most recent SEC filing. 91.47% of the stock is currently owned by institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.